SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax might be used in patients with chronic lymphocytic leukemia.